| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;47:580.)
© 2006 American Heart Association, Inc.
Part 2 Original Articles |
From the Division of Hypertension and Vascular Research, Henry Ford Hospital, Detroit, Mich.
Correspondence to Jia L. Zhuo, Division of Hypertension and Vascular Research, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202. E-mail jzhuo1{at}hfhs.org
Glucagon, a major insulin counterregulatory hormone, binds to specific Gs proteincoupled receptors to activate glycogenolytic and gluconeogenic pathways, causing blood glucose levels to increase. Inappropriate increases in serum glucagon play a critical role in the development of insulin resistance and target organ damage in type 2 diabetes. We tested the hypotheses that: (1) glucagon induces proliferation of rat glomerular mesangial cells through glucagon receptoractivated phosphorylation of mitogen-activated protein kinase extracellular signalregulated kinase 1/2 (p-ERK 1/2); and (2) this phosphorylation involves activation of cAMP-dependent protein kinase A (PKA) and phospholipase C (PLC)/[Ca2+]i signaling pathways. In rat mesangial cells, glucagon (1 nM) stimulated [3H]-thymidine incorporation by 96% (P<0.01). This proliferative effect was blocked by the specific glucagon receptor antagonist [Des-His1-Glu9] glucagon (1 µmol/L; P<0.01), a mitogen-activated protein kinase/ERK kinase inhibitor PD98059 (10 µmol/L; P<0.01), a PLC inhibitor U73122 (1 µmol/L; P<0.01), or a PKA inhibitor H-89 (1 µmol/L; P<0.01). The proliferation was associated with a 2-fold increase in p-ERK 1/2 that peaked 5 minutes after glucagon stimulation (P<0.01) and also was blocked by [Des-His1-Glu9] glucagon. Total ERK 1/2 was not affected by glucagon. Pretreating of mesangial cells with U73122 or H89 significantly attenuated ERK 1/2 phosphorylation induced by glucagon. We believe that these are the first data showing that glucagon activates specific receptors to induce ERK 1/2 phosphorylation and thereby increase mesangial cell proliferation and that this effect of glucagon involves both PLC/[Ca2+]i- and cAMP-dependent PKA-activated signaling cascades.
Key Words: kidney cyclic AMP calcium diabetes mellitus glomerulosclerosis insulin resistance
This article has been cited by other articles:
![]() |
J. A. Harney and R. L. Rodgers Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E155 - E161. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. C. Li and J. L. Zhuo Selective knockdown of AT1 receptors by RNA interference inhibits Val5-ANG II endocytosis and NHE-3 expression in immortalized rabbit proximal tubule cells Am J Physiol Cell Physiol, July 1, 2007; 293(1): C367 - C378. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. ZHUO, O. A. CARRETERO, and X. C. LI Effects of AT1 Receptor-Mediated Endocytosis of Extracellular Ang II on Activation of Nuclear Factor-{kappa}B in Proximal Tubule Cells Ann. N.Y. Acad. Sci., December 1, 2006; 1091(1): 336 - 345. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |